[go: up one dir, main page]

MA32764B1 - Inhibiteurs de l'intégrase du vih - Google Patents

Inhibiteurs de l'intégrase du vih

Info

Publication number
MA32764B1
MA32764B1 MA33804A MA33804A MA32764B1 MA 32764 B1 MA32764 B1 MA 32764B1 MA 33804 A MA33804 A MA 33804A MA 33804 A MA33804 A MA 33804A MA 32764 B1 MA32764 B1 MA 32764B1
Authority
MA
Morocco
Prior art keywords
hiv
compounds
inhibitors
antigrade
prophylaxis
Prior art date
Application number
MA33804A
Other languages
Arabic (ar)
English (en)
Inventor
Richard C A Isaacs
Wayne J Thompson
Peter D Williams
Dai-Shi Su
Shankar Venkatraman
Mark W Embrey
Thorsten E Fisher
John S Wai
David C Dubost
Richard G Ball
Eric J Choi
Tao Pei
Sarah L Trice
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32764B1 publication Critical patent/MA32764B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) QUI SONT DES INHIBITEURS DE L'INTÉGRASE DU VIH ET DES INHIBITEURS DE LA RÉPLICATION DU VIH. DANS LA FORMULE (I), X1, X2, Y, R1A, R1B, R2 ET R3 SONT DÉFINIS DANS LA DESCRIPTION. CES COMPOSÉS SONT UTILES DANS LA PROPHYLAXIE OU LE TRAITEMENT D'UNE INFECTION PROVOQUÉE PAR LE VIH ET LA PROPHYLAXIE, LE TRAITEMENT OU LE RETARDEMENT DU DÉCLENCHEMENT OU DE LA PROGRESSION DU SIDA. LES COMPOSÉS SELON L'INVENTION SONT UTILISÉS POUR LUTTER CONTRE UNE INFECTION VIH ET LE SIDA SOUS FORME DESDITS COMPOSÉS EUX-MÊMES (OU D'HYDRATES OU DE SOLVATES DE CEUX-CI) OU DE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES. CES COMPOSÉS ET LEURS SELS PEUVENT ÊTRE EMPLOYÉS EN TANT QU'INGRÉDIENTS DANS DES COMPOSITIONS PHARMACEUTIQUES, ÉVENTUELLEMENT COMBINÉS À D'AUTRES ANTIVIRAUX, IMMUNOMODULATEURS, ANTIBIOTIQUES OR VACCINS.
MA33804A 2008-10-06 2011-05-02 Inhibiteurs de l'intégrase du vih MA32764B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19527108P 2008-10-06 2008-10-06
PCT/US2009/059306 WO2010042391A2 (fr) 2008-10-06 2009-10-02 Inhibiteurs de l'intégrase du vih

Publications (1)

Publication Number Publication Date
MA32764B1 true MA32764B1 (fr) 2011-11-01

Family

ID=41682332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33804A MA32764B1 (fr) 2008-10-06 2011-05-02 Inhibiteurs de l'intégrase du vih

Country Status (22)

Country Link
US (2) US8513234B2 (fr)
EP (1) EP2349276B1 (fr)
JP (2) JP4880097B1 (fr)
KR (1) KR20110066224A (fr)
CN (1) CN102239172A (fr)
AR (1) AR073769A1 (fr)
AU (1) AU2009302663B2 (fr)
BR (1) BRPI0920605A8 (fr)
CA (1) CA2738814C (fr)
CO (1) CO6382127A2 (fr)
CR (1) CR20110184A (fr)
DO (1) DOP2011000093A (fr)
EA (1) EA201170537A1 (fr)
EC (1) ECSP11010959A (fr)
IL (1) IL212019A0 (fr)
MA (1) MA32764B1 (fr)
MX (1) MX2011003637A (fr)
NI (1) NI201100069A (fr)
PE (1) PE20110344A1 (fr)
TW (1) TW201020251A (fr)
WO (2) WO2010042391A2 (fr)
ZA (1) ZA201102620B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2014008636A1 (fr) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Composés macrocycliques en tant qu'inhibiteurs de l'intégrase du vih
CN102936188B (zh) * 2012-11-19 2015-07-15 湖北吉和昌化工科技有限公司 一种丙炔醇缩水甘油醚的合成方法
EP2986291B1 (fr) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
CN107722106A (zh) * 2016-08-11 2018-02-23 重庆大学 Hiv抑制剂
EP4122537A1 (fr) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Composés tricycliques pontés de carbamoylpyridone et leur utilisation pharmaceutique
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
SI4196479T1 (sl) 2021-01-19 2024-01-31 Gilead Sciences, Inc. Substituirane piridotriazinske spojine in njihove uporabe
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
MXPA04003932A (es) 2001-10-26 2004-06-18 Angeletti P Ist Richerche Bio Inhibidores de la hidroxipirimidinona carboxamida n-sustituida de la integrasa del virus de inmunodeficiencia humana.
ATE370948T1 (de) 2002-01-17 2007-09-15 Merck & Co Inc Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
HRP20050593A2 (en) 2002-12-27 2006-03-31 Instituto di Ricerche di Biologia Molecolare P. An Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004062613A2 (fr) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Inhibiteurs d'integrase hiv
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
DE602005012069D1 (de) 2004-04-06 2009-02-12 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006060225A2 (fr) * 2004-11-23 2006-06-08 Merck & Co., Inc. Processus destine a la synthese asymetrique d'hexahydropyrimido[1,2-a] azepine-2-carboxamides et de composes correspondants
CN101146811B (zh) * 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
US7897592B2 (en) 2005-11-15 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007058646A1 (fr) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Inhibiteurs d’integrase du vih : composes cycliques de la pyrimidinone
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (fr) 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Heterocycles bicycliques en tant qu'inhibiteurs de l'integrase du vih
WO2007143446A1 (fr) 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Composés hétérotricycliques spiro-condensés utilisés en tant qu'inhibiteurs de la vih intégrase
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors

Also Published As

Publication number Publication date
US8513234B2 (en) 2013-08-20
JP5600311B2 (ja) 2014-10-01
WO2010042392A3 (fr) 2010-06-03
CA2738814C (fr) 2014-01-28
JP2012504648A (ja) 2012-02-23
EP2349276A2 (fr) 2011-08-03
AR073769A1 (es) 2010-12-01
JP2012036207A (ja) 2012-02-23
WO2010042391A2 (fr) 2010-04-15
US20100087419A1 (en) 2010-04-08
CN102239172A (zh) 2011-11-09
BRPI0920605A8 (pt) 2016-04-26
ECSP11010959A (es) 2011-05-31
ZA201102620B (en) 2011-12-28
CA2738814A1 (fr) 2010-04-15
AU2009302663B2 (en) 2012-11-08
US20130338141A1 (en) 2013-12-19
AU2009302663A1 (en) 2010-04-15
WO2010042392A2 (fr) 2010-04-15
EA201170537A1 (ru) 2011-12-30
IL212019A0 (en) 2011-06-30
BRPI0920605A2 (pt) 2015-12-22
MX2011003637A (es) 2011-04-27
TW201020251A (en) 2010-06-01
NI201100069A (es) 2012-08-08
WO2010042391A3 (fr) 2010-06-03
CO6382127A2 (es) 2012-02-15
JP4880097B1 (ja) 2012-02-22
CR20110184A (es) 2011-06-08
DOP2011000093A (es) 2011-07-15
PE20110344A1 (es) 2011-06-22
EP2349276B1 (fr) 2019-11-27
KR20110066224A (ko) 2011-06-16

Similar Documents

Publication Publication Date Title
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA29745B1 (fr) Inhibiteurs de la transcriptase inverse du vih
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MA44674B1 (fr) Inhibiteurs de bromodomaine
TN2011000316A1 (fr) Derives de sulfonamides
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31754B1 (fr) Cis-imidazolines chirales
TN2009000450A1 (fr) Derives de pyridine
MA42292A (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
TNSN07022A1 (fr) Derives de pyridine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
WO2009146555A8 (fr) Inhibiteurs de l'intégrase du vih, issus de la pyridoxine
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
TNSN08139A1 (fr) Composes therapeutiques
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
WO2005086700A3 (fr) Inhibiteurs de l'integrase du vih
WO2008132138A9 (fr) Dérivés d'aminopyrimidines disubstituées en 4 et en 6
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse